Studies

Indication: Overactive Bladder Syndrome

Type of Study: Phase 1 Study

Sponsor: CRO

Patient Population: 60

Investigative Sites: 5

ViewPoint FUSE Team partnered with a CRO to support the development and management of this small Phase 1 study. The goal of this study was to evaluate the safety and the potential activity of treatment with three dose levels in women with overactive bladder syndrome (OAB). OAB is characterized by a decreased bladder capacity, frequent voiding, frequent sensations of a strong urge to void, and in some patients, episodes of incontinence. The target population is women with OAB and detrusor overactivity (DH) who have been unable to tolerate, do not wish to continue, or have had unsuccessful results with prior therapy. Subjects participated for 6 months with annual follow-up visits for up to 15 years.